



July 29, 2022

Li Yan  
Manager of Regulatory Affairs  
Fujian Shengdi Pharmaceutical Co., Ltd.  
308 Wengjiao Road, Haicang District  
Xiamen, Fujian, China

*Sent via email to:* [li.yan@hengrui.com](mailto:li.yan@hengrui.com)

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drugs designate Dextrose 2.5% and Sodium Chloride 0.45% Injection in Plastic Container (2.5GM/100ML; 450MG/100ML) from FRESENIUS KABI USA LLC with the application No. A211190 as an additional RS for Dextrose 2.5% and Sodium Chloride 0.45% Injection (2.5GM/100ML; 450MG/100ML) was received and processed under CFR 10.30 by this office on 07/28/2022.

It was assigned docket number FDA-2022-P-1739. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Karen Malvin  
Acting Director  
Dockets Management Staff  
FDA/Office of Operations (OO)